FDA 21 CFR Part 11 governs electronic records and electronic signatures in FDA-regulated industries, pharmaceutical, biotechnology, medical device, and food manufacturers subject to FDA oversight.
CMMS falls under Part 11 scope when it generates, modifies, or manages records that would otherwise be required in paper form under FDA regulations, including equipment maintenance records, calibration records, preventive maintenance completion logs, and corrective action work orders.
The core Part 11 requirements that CMMS must satisfy: audit trails that capture who created, modified, or deleted a record with timestamp and reason for change, and these audit trails must be computer-generated, not user-editable electronic signature capability where signatures are uniquely linked to the individual signing and cannot be transferred or shared
access controls that restrict record creation and modification to authorized users with role-based permissions system validation documentation ( IQ/OQ/PQ ) demonstrating the system performs as intended and data integrity controls ensuring records cannot be altered without audit trail capture.
CMMS vendors who claim "21 CFR Part 11 compliance" without providing their validation documentation package and audit trail architecture details are making a marketing claim, not a technical one.
FDA-regulated manufacturers must validate computerized systems that affect product quality or regulatory records. CMMS is explicitly in scope.
The validation framework requires Installation Qualification (IQ, verifying the system is installed correctly), Operational Qualification (OQ, verifying the system performs according to specifications), and Performance Qualification (PQ, verifying the system performs correctly in the actual manufacturing environment).
CMMS vendors with pharma experience provide a Vendor Assessment Report (VAR) and Installation Qualification support documents that reduce the manufacturer's validation burden, but the manufacturer is ultimately responsible for the validation.
Expect to spend 200-600 hours on CMMS validation for a mid-size pharma deployment, depending on system complexity and the maturity of the vendor's validation documentation package.
Key questions to ask CMMS vendors during pharma procurement: Do you provide a validated instance or a standard instance requiring customer validation? What is included in your validation documentation package (protocols, test scripts, summary report templates)?
Do you notify customers of system changes that may require re-validation? How are software updates managed to preserve validation status?
Use this checklist when evaluating CMMS vendors for FDA-regulated pharmaceutical or medical device manufacturing.
Audit trail requirements: confirm the system generates an immutable, computer-generated audit trail for all record creation, modification, and deletion, and demonstrate this in the vendor demo by creating and modifying a work order, then viewing the complete audit trail.
Electronic signature: confirm signatures are bound to unique user credentials, require re-authentication at signature time, and are captured with date/time stamp and meaning (approved, reviewed, executed).
Access controls: confirm role-based access with documented permission matrix, and verify that access changes are themselves audit-trailed.
Data integrity: ask whether records stored in the database can be modified by direct database access (a Part 11 concern for cloud and on-premise deployments) and what controls prevent this.
Vendor change control: require notification of any system change that may affect validated functionality.
Fabrico and other modern cloud CMMS platforms increasingly offer pharma-grade audit trail and electronic signature capability, but the validation package quality varies significantly, request the complete IQ/OQ protocol templates before making a selection decision.
Login
Blog
